InVivo Therapeutics (NSDQ:NVIV) yesterday presented twelve-month results from the single-arm INSPIRE study of its neuro-spinal scaffold. The Cambridge, Mass.-based company’s neuro-spinal scaffold is a novel, biodegradable device designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting. Results from the trial were presented at the 2019 AANS Meeting in […]
JenaValve names Kilcoyne as CEO | Personnel Moves – January 15, 2019
JenaValve Technology said today that it named former ReVision Optics prez & CEO John Kilcoyne as its new chief executive officer, effective immediately, replacing Dr. Victoria Carr-Brendell, who has taken up an executive leadership position with Sonova Holding AG (SIX:SOON). Prior to his time at ReVision Optics, Kilcoyne served as prez & CEO at Micrus Endovascular where he […]
InVivo inks joint research deal with cell therapy dev Q Therapeutics
InVivo Therapeutics (NSDQ:NVIV) said today it inked a joint research agreement with clinical-stage central nervous system cell therapy developer Q Therapeutics. Through the deal, InVivo is looking to combine its neuro-spinal scaffold technology with Q Therapeutics’ adult neural progenitor cells, Cambridge, Mass.-based InVivo said. Both companies will share their technologies and explore the potential combination’s safety […]
InVivo touts 1-year Inspire study results
InVivo Therapeutics (NSDQ:NVIV) today released 12-month results from the closed Inspire study of its neuro-spinal scaffold, touting improvements in ASIA impairment scales. The Cambridge, Mass.-based company’s neuro-spinal scaffold is a novel, biodegradable device designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting. Of the 16 patients in […]
InVivo Therapeutics shares down as losses grow in Q2 earnings release
Shares in InVivo Therapeutics (NSDQ:NVIV) fell today after the medical device maker missed expectations on Wall Street with its second quarter results. The Cambridge, Mass-based company posted losses of $12.9 million, or $7.48 per share, up 104.1% as compared with the same period during the previous year. Losses per share were well behind the 41¢ expectations […]
InVivo closes $15m round
InVivo Therapeutics (NSDQ:NVIV) said today it closed a new public offering, bringing in approximately $15.2 million. In the round, the Cambridge, Mass.-based company floated 388,000 shares and another 388,000 warrants at a combined price of $2 per unit, plus 6.2 million pre-funded warrants and 6.2 million standard warrants at $1.99 apiece. The round also included an […]
InVivo Therapeutics prices $13m offering
InVivo Therapeutics (NSDQ:NVIV) today priced a public stock offering worth more than $13 million for the neurospinal scaffold it’s developing to treat spinal cord injuries. Cambridge, Mass.-based InVivo said it plans to float some 388,000 shares and another 388,000 warrants at a combined price of $2 per unit, plus 6.2 million pre-funded warrants and 6.2 million […]
InVivo prices $11m offering
InVivo Therapeutics (NSDQ:NVIV) has registered for a new offering of shares and warrants that could bring in approximately $11 million, according to an SEC filing. In the offering, the company will look to float approximately 1.5 million shares and 1.5 million Series A warrants at $7.40 per share. InVIvo Therapeutics has not yet announced the exercise […]
UPDATE: InVivo shares surge on release of 6-month results from cancelled Inspire trial
InVivo Therapeutics (NSDQ:NVIV) today has seen shares rise as much as 75% after it released complete six-month results from the company’s Inspire study of its neuro-spinal scaffold, which it ended in January after halting enrollment last July. Results were presented by Dr. Stuart Lee of Vidant Health at the 2018 AANS meeting yesterday, the Cambridge, Mass.-based […]
InVivo Therapeutics registers $8m offering
InVivo Therapeutics (NSDQ:NVIV) today registered for an upcoming offering, looking to raise approximately $8 million, according to an SEC filing. In the offering, the Cambridge, Mass.-based company will look to offer shares of common stock and Series A warrants. The offering is slated to include a 45-day underwriter’s option for the purchase of additional shares, according […]
InVivo plans 1-for-25 reverse stock split
InVivo Therapeutics (NSDQ:NVIV) said today it is initiating a 1-for-25 reverse split of its stock, looking to put a single share in the hands of its shareholders for every 25 shares they previously owned. The move will reduce the company’s authorized shares from 100 million to just four million, the Cambridge, Mass.-based company said, and is […]
- 1
- 2
- 3
- …
- 17
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube